BioNTech SE (BNTX)
| Market Cap | 22.44B -15.6% |
| Revenue (ttm) | 3.37B +4.3% |
| Net Income | -1.33B |
| EPS | -5.52 |
| Shares Out | 251.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,573,353 |
| Open | 89.00 |
| Previous Close | 89.31 |
| Day's Range | 87.16 - 89.62 |
| 52-Week Range | 79.52 - 124.00 |
| Beta | 1.53 |
| Analysts | Strong Buy |
| Price Target | 134.15 (+50.27%) |
| Earnings Date | Mar 10, 2026 |
About BNTX
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli... [Read more]
Financial Performance
In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for BNTX stock is "Strong Buy." The 12-month stock price target is $134.15, which is an increase of 50.27% from the latest price.
News
BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript
BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript
BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls
The company guided 2026 total revenue to roughly $2.2–$2.5 billion, below Street expectations, stating that Covid will be a smaller contributor going forward and growth will depend increasingly on the...
BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of BioNTech SE (NASDAQ: BNTX). The investigation focuses on BioNTech's execu...
One simple reason why BioNTech stock is a raging buy on today's crash
BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock crashed more than 20%, mostly because its cofounders, Ugur Sahin (CEO) and O...
BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture
With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike.
Scientists behind COVID-19 vaccine will depart BioNTech
The company's co-founders said they are leaving to start a new mRNA-based company.
BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.
The German biotech provides a weak full-year outlook and announces the exit of its co-founders.
BioNTech Cofounders to Leave to Form New Company
The company said its cofounders were leaving to form a biotechnology startup focused on developing messenger RNA.
BioNTech's founding couple Sahin, Tuereci to leave to set up new venture
The cofounders of BioNTech , Ugur Sahin and Oezlem Tuereci, will leave the COVID-19 vaccine maker by the end of 2026 to set up their own new company, the biotech firm said on Tuesday.
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A...
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans for an independent company to be established and led by BioNTech co-foun...
BioNTech: The Market Is Pricing Low Oncology Success
BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. At a $27.6B market cap and ~$11B enterprise value, BNTX's pipeline—includ...
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
MAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2025 on Tuesday, ...
BioNTech sues Moderna for patent infringement over COVID-19 shots
Biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNexspike infringes a patent related to BioNTech and Pfizer's competing ...
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Boa...
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company's focus areas for 2026, including an overvie...
University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund
PHILADELPHIA--(BUSINESS WIRE)--The University of Pennsylvania (“Penn”), BioNTech SE (“BioNTech”), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Innovative T...
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
MAINZ, Germany, December 18, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and that the subse...
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart
BioNTech (BNTX) maintains a "Strong Buy" rating, driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. BNTX's gotistobart delivered a 63.1% 12-month OS rate versus 30.3%...
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chem...
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLC
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expirati...
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.